Cargando…
Comments on: “In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea”
Autor principal: | Gil, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131125/ https://www.ncbi.nlm.nih.gov/pubmed/30078127 http://dx.doi.org/10.1007/s40268-018-0242-z |
Ejemplares similares
-
In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea
por: Piwnica, David, et al.
Publicado: (2018) -
Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
por: Anderson, Michael S, et al.
Publicado: (2017) -
Comment on: Feasibility and safety of vitrectomy under topical anesthesia in an office-based setting
por: Kumawat, Devesh, et al.
Publicado: (2019) -
Acute onset of necrolytic migratory erythema mimicking an erythema multiforme
por: Juśko, Natalia, et al.
Publicado: (2020) -
Botulinum Toxin A Alleviates Persistent Erythema and Flushing in Patients with Erythema Telangiectasia Rosacea
por: Yang, Rongli, et al.
Publicado: (2022)